- Home
- SAR vs CRDF Comparison
SAR vs CRDF Comparison
Compare SAR & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAR
- CRDF
- Stock Information
- Founded
- SAR 2007
- CRDF 1999
- Country
- SAR United States
- CRDF United States
- Employees
- SAR N/A
- CRDF N/A
- Industry
- SAR Investment Managers
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SAR Finance
- CRDF Health Care
- Exchange
- SAR Nasdaq
- CRDF Nasdaq
- Market Cap
- SAR 346.8M
- CRDF 288.7M
- IPO Year
- SAR 2007
- CRDF N/A
- Fundamental
- Price
- SAR $23.55
- CRDF $3.96
- Analyst Decision
- SAR Buy
- CRDF Strong Buy
- Analyst Count
- SAR 4
- CRDF 4
- Target Price
- SAR $25.08
- CRDF $12.00
- AVG Volume (30 Days)
- SAR 202.7K
- CRDF 1.1M
- Earning Date
- SAR 05-05-2025
- CRDF 05-01-2025
- Dividend Yield
- SAR 14.03%
- CRDF N/A
- EPS Growth
- SAR 33.28
- CRDF N/A
- EPS
- SAR 2.49
- CRDF N/A
- Revenue
- SAR $154,793,533.00
- CRDF $683,000.00
- Revenue This Year
- SAR $6.07
- CRDF N/A
- Revenue Next Year
- SAR N/A
- CRDF N/A
- P/E Ratio
- SAR $9.51
- CRDF N/A
- Revenue Growth
- SAR 11.52
- CRDF 39.96
- 52 Week Low
- SAR $21.56
- CRDF $2.01
- 52 Week High
- SAR $26.49
- CRDF $6.42
- Technical
- Relative Strength Index (RSI)
- SAR 33.40
- CRDF 51.25
- Support Level
- SAR $23.55
- CRDF $3.52
- Resistance Level
- SAR $26.17
- CRDF $4.31
- Average True Range (ATR)
- SAR 0.47
- CRDF 0.39
- MACD
- SAR -0.27
- CRDF -0.06
- Stochastic Oscillator
- SAR 8.35
- CRDF 42.86
About SAR Saratoga Investment Corp New
Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests primarily in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical program in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC").